Relmada Therapeutics Targets 2026 IND Submission for NDV-01 Program
Relmada Therapeutics (RLMD) reported significant progress regarding its NDV-01 program during the third quarter. CEO and Director Sergio Traversa confirmed that the company is currently on track to submit an Investigational New Drug (IND) application by the end of 2026. In addition to clinical development milestones, the company highlighted a strong financial position, noting a cash runway that extends through 2029. This liquidity provides a stable foundation for continued research and development activities over the coming years.
Tickers: $RLMD
Topics: clinical trials drug development IND submission quarterly results